Tango Therapeutics (NASDAQ:TNGX – Free Report) had its price objective lowered by Barclays from $18.00 to $13.00 in a report published on Friday morning, Benzinga reports. The brokerage currently has an overweight rating on the stock. A number of other equities analysts have also recently commented on TNGX. Cantor Fitzgerald initiated coverage on shares of […]
StockNews.com downgraded shares of Merus (NASDAQ:MRUS – Free Report) from a hold rating to a sell rating in a research note issued to investors on Wednesday. A number of other equities analysts also recently issued reports on the company. Truist Financial assumed coverage on Merus in a research note on Thursday, March 28th. They set […]
HC Wainwright restated their buy rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a report published on Thursday morning, Benzinga reports. HC Wainwright currently has a $54.00 price objective on the stock. Other equities research analysts also recently issued reports about the stock. SVB Leerink assumed coverage on shares of Cartesian Therapeutics […]
Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price target increased by Morgan Stanley from $50.00 to $70.00 in a research note released on Thursday, Benzinga reports. They currently have an overweight rating on the stock. Other analysts also recently issued research reports about the stock. Robert W. Baird raised their price target on shares […]
JPMorgan Chase & Co. initiated coverage on shares of Structure Therapeutics (NASDAQ:GPCR – Free Report) in a research note published on Tuesday morning, Marketbeat Ratings reports. The firm issued an overweight rating and a $65.00 target price on the stock. Several other brokerages have also recently commented on GPCR. Lifesci Capital reaffirmed an outperform rating […]